December 10, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC)today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of his “Forsythe Immune Therapy” (FIT).

As previously announced, James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Board of Directors and Head of the Scientific Advisory Board, was featured in Suzanne Somers’ book Knockout. Due to the overwhelming response to the information and protocol featured in Ms. Somers’ book, Dr. Forsythe’s clinic has become inundated with new patient requests and referrals. Due to this dramatic increase in both new patient inquiries and volume, it has become necessary to increase the staff at Dr Forsythe’s facility, The Cancer Screening and Treatment Center of Nevada.

With the increase in new patient inquiries coupled with the demonstrated efficacy of Dr. Forsythe’s protocol, HST Global intends to expedite the opening of its FIT Certified clinics. In a focused effort to properly train the physicians and support staff in these clinics, HST Global and Dr. Forsythe have agreed to develop and implement the curriculum for the licensing and/or certification of physicians and support staff in the administration of Dr. Forsythe’s FIT protocol.

Read the full news release on BusinessWire.com

October 26, 2009

DR. JAMES FORSYTHE, A MEMBER OF HST GLOBAL’S BOARD OF DIRECTORS AND
 SCIENTIFIC ADVISORY BOARD, FEATURED IN SUZANNE SOMERS’ NEW BOOK
 KNOCKOUT

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced that  James W. Forsythe, MD, HMD, board certified oncologist and a member of HST Global Inc.’s Scientific Advisory Board, has been featured in Suzanne Somers’ new book Knockout.   

In Knockout, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments—treatments that build up the body rather than tear it down. Somers herself has stared cancer in the face, and a decade later she has conquered her fear and has emerged confident in the path she has chosen. 

Ms. Somers shares her personal choices and outlines an array of options from doctors across the country which includes effective alternative treatments without chemotherapy, radiation and sometimes eliminating surgery.  She also explores integrative protocols that combine standard treatments with therapies that build up the immune system and outlines methods for managing cancer to truly live with the disease.   Since prevention is the best course, Doctors interviewed in Knockout provide nutrition, lifestyle, and dietary supplementation options to help protect you from contracting the disease in the first place.   

Ms. Somers is quoted by the AP as stating of her latest book in an interview, “Cancer’s an epidemic… and yet we keep going back to the same old pot, because it’s all we’ve got. Well, this is a book about options.”  Dr. Forsythe further stated, “For years I have dedicated my practice to offering cancer patient’s traditional oncology as well as science-based integrative treatment options.  I am honored that Ms. Somers has chosen to interview me and highlight my work in her new book.”

Mr. Ron Howell, CEO and President of HST Global Inc., stated, “We are impressed with Ms. Somers’ latest book, Knockout.  Her passion, experience, and personal commitment to alternative methods in treating cancer are evident throughout her writings and she has worked hard to validate treatment alternatives for this life threatening disease.  We are pleased that she has dedicated a chapter in her new book to a member of our Company.  This is further confirmation of the strategic direction that both Dr. Forsythe and HST Global have taken in providing alternative health care options for those who are suffering from late stage cancer.”

Wes Tate, CFO, stated “I am excited about the fact that Dr. Forsythe and HST Global’s protocols have now moved into the national spotlight and how this news can benefit our shareholders in both their personal and economic interests.   We continue everyday to substantiate shareholder value through pioneering new technologies that enhance quality of life.”

Read the full news release on BusinessWire.com

October 8, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced a strategic R&D alliance with Dr. James W. Forsythe for the research and development of HST’s exclusive Nutraceutical and Medical Food formulation platform. Dr. Forsythe brings over thirty years of medical and research experience including expertise in the research and clinical application of Nutraceutical and Medical Food products.

"Dr. Forsythe’s well established experience in the medical community will be a valuable asset in the development of our exclusive brand of products," said Ron Howell, CEO and President of HST Global, Inc. "James will be instrumental in the acquisition of new technologies in the emerging field of science-based Nutraceuticals." Dr. Forsythe is a past Associate Professor of Medicine and Pathology, University of Nevada Medical School Reno, NV. Prior to that, he was an instructor in Medicine and Hematology, University of California Medical Center, San Francisco, CA.

Dr. Forsythe currently serves on HST Global Inc.’s Scientific Advisory Board. He received his Doctorate of Medicine from the University of California, San Francisco and his Undergraduate Degree from University of California at Berkeley. Dr. Forsythe is certified in Homeopathy and Board Certified in Internal Medicine, Medical Oncology and Utilization Review and Quality Assurance. He is also Board eligible in Clinical Pathology and Medical Gerontology. Dr. Forsythe is also the owner and Medical Director of Cancer Screening and Treatment Center of Nevada and Century Wellness Clinic. In addition, Dr. Forsythe spent 26 years in the United States Army Medical Corps, retiring full Colonel. He was also the former State Surgeon in the Nevada Army National Guard.

Read the full news release on BusinessWire.com

August 20, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) announced it is one of several companies that are showcasing their business and products at the annual World Money Show being held August 21-23, 2009 in San Francisco, CA at the San Francisco Marriott. HST Global, Inc. will be located at Booth number 612. For additional information, contact our Investor Relations Department at (757) 766-6100 or e-mail at ir@hstglobal.com.

Read the full news release on BusinessWire.com

August 19, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced the official launch of the FocusUP Website located at www.focusup.com. FocusUP is the cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.).

Ron Howell, CEO/President stated, “We are pleased to announce the launch of our new FocusUP® website. With the introduction of the new website, we will have the ability to educate the public on the benefits of FocusUP ®, Dr. Kyl Smith’s cognitive function product. We encourage you to go to www.focusup.com to learn more.”

Product and ordering information regarding FocusUP® can be found at www.focusup.com. You can also visit www.brightermind.com to find out more information about Dr. Kyl Smith.

Read the full news release on BusinessWire.com

August 10, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced it will issue its second quarter results on Friday, August 14, 2009.

Read the full news release on BusinessWire.com

August 7, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced that it is offering free samples of FocusUP®, its new cognitive function product endorsed and recommended by Dr. Kyl Smith.

Ron Howell, CEO/President stated, “With the impending launch of the FocusUP® campaign, we recognize the importance of establishing brand name recognition and wide scale market exposure. As a result, we are offering free samples of FocusUP® to the first 1,000 individuals that e-mail the company requesting our new product.”

To request free samples of FocusUP®, please e-mail the company at freeoffer@hstglobal.com and provide the following:

Read the full news release on BusinessWire.com

July 21, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced the launch of a cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.). The Company intends to launch the new product on August 1, 2009. The new product will be named Focus-Up®.

Ron Howell, CEO/President stated, “With the North American Baby Boomer population standing at 80 million, one out of every three Americans will be age 50 or over by 2010. These facts, in conjunction with continued advances in age and condition-specific products and technologies bode well for the industry as a whole. There is an especially robust market for Focus-Up®, particularly among these older consumers. In fact, market research shows that this category will lead gains in its $20 billion industry in the US alone.”

Dr. Kyl Smith stated, “HST plans to mature the expansion and development of two unique product lines; a physician-formulated 'all natural' nutritional product line designed to address wellness challenges and provide preventative maintenance and support overall health; and a Medical Food line providing new and novel physician-based therapeutic approaches that positively impact patients with immune and degenerative disorders, who are in need of effective, well-tolerated treatments. This will allow HST to concentrate on the acquisition of patent applications and technologies that the company controls from formulation through to consumer application as well as integrating the educational process necessary to help patients understand the underlying need for good nutrition in achieving and maintaining optimum health.”

More information about our new product can be found at www.focusup.com. You can also visit www.brightermind.com to find out more information about Dr. Kyl Smith.

Read the full news release on BusinessWire.com

July 9, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced the execution of a Joint Venture agreement with Dalham, LLC (an affiliate company of The Health Network, Inc.). This agreement capitalizes on several years of research and development initiated by The Health Network (THN) for the establishment of cutting edge technologies associated with an individual’s mood, memory and mind development. THN spent over one (1) year developing an “all natural” energy drink before partnering with Dr. Kyl Smith. Dr. Smith has over seventeen (17) years experience in the study and development of cognitive enhancing products and programs founded on a platform of peer-reviewed scientific substantiation.

Dr. Smith is a #1 Best-selling Nutrition Inventor who is the architect behind the formulation, development and marketing of several products including a hundred-million dollar brand establishing an unprecedented industry benchmark through record sales. In addition, Dr. Smith is known for another unprecedented accomplishment: He acquired the first nutrient-based Qualified Health Claim for cognitive function to be approved in the FDA’s history. Ultimately he spent several years in research culminating in the book: Brighter Mind. This book is a compilation of his life’s work and resulted in the presentation of significant scientific advances in the area of cognitive function as substantiated thru peer-reviewed scientific literature. This scientific validation independently provided THN the basis to formulate a proprietary and advanced product focusing on brain function.

Ron Howell, stated “We feel proud and privileged to effectuate a Joint Venture with Dalham, LLC. This initiative will afford us the opportunity to continue our mission of providing 'break-through' technologies that will serve to improve an individual’s well being. To our knowledge, this product will be the first in the Functional Beverage category positioned as an 'all natural' energy 'Think Drink.' The scientific evidence supporting the ingredients will afford us the opportunity to create marketing literature that details the products contributions to cognitive function and overall health. The Joint Venture will provide the companies a high position of visibility with access to thousands of independent distributors serving communities in over 50 countries.”

Read the full news release on BusinessWire.com

June 9, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today released an update to its recent announcements pertaining to the acquisition of clinics and companies worldwide that have developed and are developing protocols for the care of late stage cancer patients using a variety of immunotherapy treatments.

Ron Howell, President and CEO of HST Global, Inc. stated "HST is committed to the acquisition and development of Health and Wellness Centers that exhibit success with immunotherapy therapies. Alternative therapies are achieving extraordinary degrees of success, as demonstrated by companies such as Dendreon Corporation (NASDAQ: DNDN) whose immunotherapy prostate-cancer drug Provenge was found to extend survival rates."

HST’s recent announcement to acquire Bryomed International (www.bryomed.net) is the next phase of the company’s overall strategic plan. The pending acquisition involves a family of immunotherapy products that include over 8,000 completed Case Studies and have been registered for the treatment of patients as an adjunct therapy before, during and after traditional cancer treatments. The 20 million dollar cash, stock and royalty Agreement will secure the exclusive worldwide rights to ten (10) existing and all future Immunotherapy products. These products have been registered by the respective Government Health Agencies in the CA-4 Nations (Guatemala, Honduras, Nicaragua and El Salvador) and Belize. Additionally, one (1) of the existing products has qualified for registration with the United States Food and Drug Administration (FDA) for use as a prescription based, NDC registered product.

Read the full news release on BusinessWire.com

May 26, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced it has entered into a Letter of Intent to acquire the assets of a Central American Immunotherapy Company. The acquisition will include a family of immunotherapy products that have been approved for the treatment of patients as an alternative to or as an adjunct therapy before, during and after traditional cancer treatments. HST anticipates completing the pending acquisition of the company at the conclusion of the due diligence period.

This pending acquisition is a part of the evolution of HST’s development of a global presence in the emerging immunotherapy treatment of cancer. The 20 million dollar cash, stock and royalty Agreement will secure the exclusive worldwide rights to ten (10) existing Immunotherapy products. These products have been registered by the respective Government Health Agencies in the CA-4 Nations (Guatemala, Honduras, Nicaragua and El Salvador) and Belize. Additionally, one (1) of the existing products has qualified for registration with the United States Food and Drug Administration (FDA) for use as a prescription based, NDC registered product. The application process has been completed on three (3) additional products. HST expects qualification for registration of these products within the next ninety (90) days. Furthermore, HST expects to make application for FDA registration on an additional two (2) products within the next sixty (60) days.

Ron Howell, President and CEO of HST Global, Inc. stated "HST is excited to have completed the necessary documentation to move forward with this acquisition. These Immunotherapy technologies have been researched, developed and refined over several years, with over 8,000 case studies substantiating the efficacy of the product application. The acquisition of these proven technologies is a major step in the global expansion plans of our wellness centers. We expect the due diligence period to conclude quickly."

Read the full news release on BusinessWire.com

April 17, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced it is reaching across the globe to insure that immunotherapy and alternative treatments and solutions are available to all communities. Alternative therapies are achieving extraordinary degrees of success, as demonstrated by companies such as Dendreon Corporation (NASDAQ:DNDN) whose immunotherapy prostate-cancer drug Provenge was found to extend survival rates. HST anticipates completing the acquisition of the center in the next ninety (90) days.

Ron Howell, President and CEO of HST Global, Inc. stated, “HST is excited to have completed the initial documentation necessary to initiate the acquisition of our first Health and Wellness Center. As stated previously, the company intends to open three (3) to five (5) centers worldwide during 2009. This acquisition will allow the company to provide alternative health care options for those who are suffering from late stage cancer.”

Read the full news release on BusinessWire.com

April 3, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC), an integrated biotechnology health and wellness company, today announced an initiative that has been started by EBITDA Capital, LLC on behalf of HST Global, Inc. for the placement of health and wellness center operations within the Native American Community.

HST Global, Inc. has requested that EBITDA Capital initiate negotiations with known contacts within the Native American community for the purpose of placing health and wellness centers on tribal reservations.

Mr. Chet Noblett, Managing General Partner, is assisting with this initiative and has a strategic plan in process. Mr. Noblett says, “We are currently working with several Native American nations and they have been very receptive to the HST Global proposals. Native Americans have always believed in the concept of being healers.”

HST is reaching across the globe to insure that its treatments and solutions are available to all communities. The Native American communities are positioned in locations that make these clinics accessible to both Native and Non-Native American people.

Read the full news release on BusinessWire.com

March 4, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) CEO Ron Howell will appear on "Corporate Strategies with Tim Connolly" on March 6, 2009 at 9:30 ET. Ron & Tim will discuss HSTC’s worldwide development of Wellness Centers which focus on the alternative and homeopathic treatment of late stage cancer patients. Listeners may call in with questions live and toll free at 800-336-2225.

Previous guests of the show have included CNBC “Mad Money” Host Jim Cramer, U.S. Senator and Presidential Candidate John McCain, former SEC Chairman Arthur Levitt, Enterprise Products CEO Dan Duncan, Celgene's CEO John Jackson, Landry's CEO Tilman Fertitta, Mario Gabelli, former Compaq CEO Eckard Pfeiffer, Money Manager Louis Navellier, and many others. Natural Nutrition, Inc. (OTCBB: NTNI - News) (www.naturalnutritioninc.com) and InterACTIVE Nutrition International, Inc. are the lead sponsors of the Corporate Strategies Radio Show, (www.corporate-strategies.net).

Corporate Strategies may be heard on over 400 affiliate stations nationwide listed at CRN1 www.cableradionetwork.com, or on the internet at www.corporate-strategies.net/radio. This hour of "Corporate Strategies with Tim Connolly" is hosted by Tim Connolly of Corporate Strategies Merchant Bankers (www.corporate-strategies.net). Noted Economist Mike King of Princeton Research provides live technical analysis for the show, and futures trader Oscar Carbone is a frequent commentator. "Corporate Strategies with Tim Connolly" is live talk radio...with the Titans of Business who move financial markets! The show is hosted by Tim Connolly, CEO of Merchant Banker Corporate Strategies, Inc. The Executive Producer of the show is broadcast news veteran Jan Carson, an award winning journalist with more than 20 years experience as a top rated television news anchor and reporter for NBC, ABC and CBS network affiliates. "Corporate Strategies with Tim Connolly" features financial experts from across the nation providing the latest intelligence on equities, income investments, and a variety of risk, equity and option strategies.

Read the full news release on BusinessWire.com

February 12, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC), an integrated biotechnology health and wellness company, today announced a project that has been initiated with EBITDA Capital, LLC for both shareholder participation and health and wellness center operations within Saudi Arabia.

HST Global, Inc has given authority to EBITDA Capital, LLC to begin working with EBITDA’s contacts and clients within the Kingdom of Saudi Arabia. Key clientele within the Royal Family have expressed an interest in becoming shareholders in HSTC. In addition, they have shown an interest in opening and operating a health and wellness clinic based within the Gulf Cooperation Council Countries (GCC). The health and wellness clinics would include both for-profit and non-profit treatment facilities in support of HSTC’s late stage cancer applications. HSTC would be responsible for the training, maintenance and management development in these clinics.

Mr. Chet Noblett, Managing General Partner of EBITDA, is currently assisting HSTC with the initial negotiations and is leveraging his long term relationships with these parties. Mr. Noblett says, "We have been cautiously opening the window of opportunity for HSTC with our associates in Saudi Arabia. Health care is a top priority throughout the GCC and HSTC offers the opportunity to energize the effort by establishing these clinics. We are very pleased to have the level of interest and acceptance that has been expressed at this time."

Ron Howell, President and CEO of HST Global, Inc., stated, "The commencement of this initiative within the GCC Countries characterizes the essence of what HSTC is developing. The combined capital and strategic operational partnership will bring an affordable, yet cost effective treatment for late stage cancer to the GCC. HSTC is reaching across the Globe with its brand of alternative health and wellness centers."

Read the full news release on BusinessWire.com

February 4, 2009
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC), an integrated biotechnology health and wellness company, today announced an initiative launched with EBITDA Capital, LLC in which medical reimbursements would be paid for its treatments.

In view of the recent changes to the federally funded Medicare Programs, through Federal reorganizations and reviews, HST Global, Inc. has launched a new initiative. The Company has requested that EBITDA Capital, LLC and its Political Affiliates initiate a dialogue with the appropriate federal agencies for the purpose of allowing the Company’s treatments for fourth stage cancer to be included in Medicare payment schedules.

Mr. Chet Noblett, Managing General Partner, and his team at EBITDA Capital have initiated a plan of action for contacting the proper government agencies. Mr. Noblett says, "The entire Federal program for medical reimbursement is being reviewed and the cost savings from HST treatments should be considered by the appropriate agencies. Not only does HST offer a credible treatment solution but the savings to taxpayers are extremely important at this time."

Ron Howell, President and CEO of HST Global, Inc. stated "As I have stated previously, there is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. In addition, the costs of these traditional alternatives have sky-rocketed over the past few years. HST is reaching across many opportunities to insure that its treatments and solutions are well recognized as not only affordable but also cost effective."

Read the full news release on BusinessWire.com

Read news from 2008.